Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global populations Commercial terms include an upfront payment and additional near-term R&D ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.

Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with ...

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...